Mr. Marc Edwards reports

KANE BIOTECH TO HOST INVESTOR WEBINAR

Kane Biotech Inc. will be hosting a webinar on Thursday, April 18, 2024, at 4:15 p.m. Eastern Time.

Marc Edwards, Kane's president and chief executive officer, will share his thoughts on what the sale of STEM Animal Health, which should ultimately net Kane more than $13-million, means for Kane as an important step in becoming a market leader in the growing high-value wound care and dermatological markets. The transaction, which focuses the company and significantly improves the balance sheet, will provide the necessary capital to achieve key milestones such as commercial launches and global growth as well as the company's clinical programs in both wound care and acne.

Participants can register for the webinar on-line.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, coactiv+, coactiv+, DermaKB, DermaKB Biofilm and revyve are trademarks of Kane Biotech. Kane is listed on the TSX Venture Exchange under the symbol KNE and on the OTCQB Venture Market under the symbol KNBIF.

We seek Safe Harbor.